Robert L. Coleman

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 42 papers. Top paper: “MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum”.

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Journal of Clinical Oncology(2020)10.1200/jco.20.01164

N/A

4.6DataRank · unranked

153 citations

Rachel N. Grisham, Susana Banerjee, Elsa Kalbacher, Mansoor Raza Mirza, Ignacio Romero +25 more

Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30081-4

N/A

4.5DataRank · unranked

90 citations

Andreas Obermair, Robert L. Coleman, René Pareja, Aldo López, Reitan Ribero +15 more

Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer

American Journal of Obstetrics and Gynecology(2020)10.1016/j.ajog.2020.08.032

N/A

4.0DataRank · unranked

125 citations

Bryan Fellman, Charlotte C. Sun, Russell R. Broaddus, Misty Woodall, Navdeep Pal +14 more

Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

Cell Reports(2020)10.1016/j.celrep.2020.03.066

N/A

2.9DataRank · unranked

143 citations

Li Zhao, Christine Rojas, Nicholas W. Bateman, Hui Yao, Olivia D. Lara +41 more

Biomarker-driven therapy in endometrial cancer

International Journal of Gynecological Cancer(2023)10.1136/ijgc-2022-003676

N/A

1.4DataRank · unranked

45 citations

Brian Slomovitz, Robert L. Coleman, Bhavana Pothuri, Hannah Karpel

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0621

N/A

0.949DataRank · unranked

22 citations

Ignace Vergote, Susana Banerjee, Esther Drill, Elsa Kalbacher, Mansoor Raza Mirza +25 more

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.045

N/A

0.920DataRank · unranked

18 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +21 more

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

International Journal of Gynecological Cancer(2024)10.1136/ijgc-2024-005919

N/A

0.812DataRank · unranked

25 citations

Bradley J. Monk, Els Van Nieuwenhuysen, Kathleen N. Moore, Michel Fabbro, David M. O’Malley +16 more

NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-19-0977

N/A

0.598DataRank · unranked

10 citations

Sunila Pradeep, Emine Bayraktar, Elaine Stur, Katelyn F. Handley, Sherry Y. Wu +6 more

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.100974

N/A

0.416DataRank · unranked

15 citations

Niya Xiong, Andrea P. Myers, Nabihah Tayob, Victoria Engvold, Madeline Polak +14 more

Executive summary of the American Radium Society® Appropriate Use Criteria for management of uterine carcinosarcoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.04.683

N/A

0.396DataRank · unranked

13 citations

Ankit Modh, Anuja Jhingran, Matthew C. Biagioli, Robert L. Coleman, David K. Gaffney +13 more

Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer

International Journal of Gynecological Cancer(2020)10.1136/ijgc-2020-001718

N/A

0.330DataRank · unranked

8 citations

Shannon N. Westin, Larissa A. Meyer, Aaron Shafer, Jose Alejandro Rauh‐Hain, Michaela Onstad +12 more

Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial

Med(2024)10.1016/j.medj.2024.07.022

N/A

0.299DataRank · unranked

4 citations

Minghao Dang, Sanghoon Lee, Bryan Fellman, Shannon N. Westin, Anil K. Sood +19 more

Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.05.022

N/A

0.241DataRank · unranked

4 citations

Krishnansu Tewari, Bradley J. Monk, Thomas J. Herzog, Robert L. Coleman, Michael T. Richardson +3 more

Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment

International Journal of Gynecological Cancer(2025)10.1016/j.ijgc.2025.101938

N/A

0.208DataRank · unranked

3 citations

Rachel N. Grisham, Robert L. Coleman, Lauren Cobb, Bradley J. Monk, Thomas J. Herzog +3 more

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.08.021

N/A

0DataRank · unranked

57 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +17 more

Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort

International Journal of Gynecological Cancer(2022)10.1136/ijgc-2022-003947

N/A

0DataRank · unranked

20 citations

Ignace Vergote, Charlotte C. Sun, Diane C. Bodurka, Robert L. Coleman, Lauren S. Prescott

Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.05.009

N/A

0DataRank · unranked

18 citations

Anil K. Sood, Graziela Zibetti Dal Molin, Shannon N. Westin, Larissa A. Meyer, Bryan Fellman +4 more

Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.11.004

N/A

0DataRank · unranked

8 citations

Siqing Fu, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Fechukwu Akhmedzhanov, Bülent Yılmaz +16 more

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

Annals of Oncology(2023)10.1016/j.annonc.2023.01.009

N/A

0DataRank · unranked

48 citations

Giuseppe Viale, Serena Nik‐Zainal, Peter Savas, Roswitha Kammler, Patrizia Dell’Orto +33 more

#267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial

International Journal of Gynecological Cancer(2023)10.1136/ijgc-2023-esgo.13

N/A

0DataRank · unranked

2 citations

Line Bjørge, Robert L. Coleman, Oleksandr Zub, Eirwen M. Miller, Roberto Angioli +15 more

Data from Therapeutic Targeting of ATP7B in Ovarian Carcinoma

(2023)10.1158/1078-0432.c.6517644

N/A

0DataRank · unranked

0 citations

Vesna Zuzel, Rosemarie Schmandt, Erik S LeShane, Jyotsna B. Halder, Guillermo N. Armaiz-Peña +16 more

Data from Therapeutic Targeting of ATP7B in Ovarian Carcinoma

(2023)10.1158/1078-0432.c.6517644.v1

N/A

0DataRank · unranked

0 citations

Vesna Zuzel, Rosemarie Schmandt, Erik S LeShane, Jyotsna B. Halder, Guillermo N. Armaiz-Peña +16 more

Data from Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models

(2023)10.1158/1535-7163.c.6543538

N/A

0DataRank · unranked

0 citations

Cristian Rodriguez‐Aguayo, Shaolin Ma, Elaine Stur, Robiya Joseph, Emine Bayraktar +17 more

Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.03.027

N/A

0DataRank · unranked

20 citations

Danielle Enserro, Matthew S. Block, Steven Waggoner, Linda Duska, Andrea E. Wahner-Hendrickson +11 more

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-3042

N/A

0DataRank · unranked

2 citations

Austin Miller, Heather A. Lankes, Kwong‐Kwok Wong, William H. Rodgers, David Millan +20 more

Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.02.015

N/A

0DataRank · unranked

2 citations

Rebecca A. Previs, Daniel Spinosa, Bryan Fellman, Amelia L. Scott, Isabelle Mulder +10 more

Multi-center, international endometrial cancer consortium highlights

International Journal of Gynecological Cancer(2025)10.1016/j.ijgc.2025.101805

N/A

0DataRank · unranked

3 citations

Anna Giudici, Vincenzo Tarantino, Stuart A. Ostby, Kelly H. Bruce, Daniel M. Breitkopf +28 more

European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis

Maturitas(2020)10.1016/j.maturitas.2020.01.005

N/A

0DataRank · unranked

99 citations

Roberto Angioli, Robert L. Coleman, Rosalind Glasspool, Francesco Plotti, Tommaso Simoncini +2 more

Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-20-0030

N/A

0DataRank · unranked

16 citations

Shaolin Ma, Anca Chelariu-Raicu, Carola Leuschner, Hector W. Alila, Sanghoon Lee +3 more

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Gynecologic Oncology Reports(2020)10.1016/j.gore.2020.100546

N/A

0DataRank · unranked

18 citations

Zhenying Tan‐Wasielewski, Carol Aghajanian, Robert L. Coleman, Jennifer Curtis, Michelle S. Hirsch +6 more

PARP inhibition in the ovarian cancer patient: Current approvals and future directions

Pharmacology & Therapeutics(2020)10.1016/j.pharmthera.2020.107588

N/A

0DataRank · unranked

16 citations

Monica Avila, Emily Hinchcliff, Robert L. Coleman, Shannon N. Westin, Katherine C. Kurnit

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer

Obstetrical & Gynecological Survey(2020)10.1097/ogx.0000000000000777

N/A

0DataRank · unranked

6 citations

Nick M. Spirtos, Danielle Enserro, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong +19 more

The incidence of myelodysplastic syndrome in patients receiving poly-ADP ribose polymerase inhibitors for treatment of solid tumors: A meta-analysis.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3641

N/A

0DataRank · unranked

6 citations

Allison Gockley, Jessica L. Floyd, Robert L. Coleman, Alexander Melamed, Jose Alejandro Rauh‐Hain +1 more

ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2021-002921

N/A

0DataRank · unranked

232 citations

René Pareja, Aldo López Blanco, José Humberto Tavares Guerreiro Fregnani, André Lopes, Myriam Perrotta +17 more

Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.03.011

N/A

0DataRank · unranked

46 citations

Alexander Melamed, Allison Gockley, Jessica L. Floyd, Kate J. Krause, Robert L. Coleman +5 more

CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance

Cell Reports(2021)10.1016/j.celrep.2021.109549

N/A

0DataRank · unranked

41 citations

Lingegowda S. Mangala, Wen Hu, Emine Bayaktar, Akira Yokoi, Wei Hu +19 more

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2020-002240

N/A

0DataRank · unranked

15 citations

Domenica Lorusso, Amit M. Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean +18 more

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Cancer Medicine(2021)10.1002/cam4.4260

N/A

0DataRank · unranked

6 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo +19 more

EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5505

N/A

0DataRank · unranked

83 citations

Robert L. Coleman, Bryan Fellman, Ying Yuan, Anil K. Sood, Pamela T. Soliman +15 more

Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5565

N/A

0DataRank · unranked

0 citations

Siqing Fu, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Fechukwu Akhmedzhanov, Bülent Yılmaz +15 more

Endometrial carcinosarcoma

International Journal of Gynecological Cancer(2022)10.1136/ijgc-2022-004073

N/A

0DataRank · unranked

95 citations

Isabelle Ray‐Coquard, Nicole Concin, Natalie Y.L. Ngoi, Philippe Morice, Giuseppe Caruso +35 more